Sergio A. Giralt, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY, provides an overview of the latest developments in the field of multiple myeloma, including depth of response associated with a four-drug induction, as well as the use of combined carfilzomib lenalidomide maintenance therapy as evaluated in a recent study. Dr Giralt continues to discuss the role of allogeneic transplantation in patients with multiple myeloma and highlights the need for a better understanding of how to sequence therapies for patients. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.